A10BK03 - Empagliflozin |
Propably not porphyrinogenic |
PNP |
Side effects
Genital and urinary tract infections are common side effects of empagliflozin that might potentially be porphyrinogenic.
Rationale
Empagliflozin is not an inducer or an inhibitor of CYP enzymes and is therefore probably not porphyrinogenic.
Chemical description
Empagliflozin is a selective and reversible inhibitor of sodium-glucose co-transporter 2 (SGLT2).
Therapeutic characteristics
Empagliflozin is an anti-diabetic indicated in adults with type 2 diabetes mellitus to improve glycaemic control. It is administered orally.
Metabolism and pharmacokinetics
In vitro data suggest that the primary route of metabolism of empagliflozin in humans is glucuronidation by the uridine 5'-diphospho-glucuronosyltransferases UGT2B7, UGT1A3, UGT1A8, and UGT1A9. Empagliflozin does not inhibit, inactivate, or induce CYP450 (FDA drug label). Interaction studies has not shown any potential for empagliflozin to affect the CYP metabolism of other drugs (Macha 2013a,b)
References
- Scientific articles
- Macha S, Rose P, et al. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Diabetes Obes Metab. 2013a Apr;15(4):316-23. #3215
- Macha S, Sennewald R, et al. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Clin Ther. 2013b Mar;35(3):226-35. PMID 23497760. #4769
- Government bodies
- U.S. Food and Drug Administration (FDA). Label information. Jardiance. (Revised: December. 2015). #3218
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Jardiance. #3217
Similar drugs
© NAPOS 2024